In Multiple Myeloma (MM), abnormal plasma cells accumulate in the bone marrow, and may also produce abnormal antibodies called M-proteins. While oncogenic plasma cells reside in the bone marrow, and few circulate in the blood; in contrast, the M-protein is often abundantly secreted into the blood. Our EasyM™ test precisely and sensitively captures the unique protein sequences from patient-specific M-proteins to reliably and routinely monitor MM patients from diagnosis through treatment and remission.
The technology behind EasyM™ is rooted in our company, Rapid Novor’s, established de novo protein sequencing platform, and decades of proteomics expertise. Home to Canada’s largest privately-owned MS proteomics facility, the Rapid Novor team has successfully integrated our machine learning algorithms and industry-leading equipment to routinely sequence complex samples in high throughput. As such, our established proprietary de novo protein sequencing and MS-based targeted approaches give EasyM™ our competitive advantage.
Options include serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), multicolor flow cytometry (MFC), and next-generation sequencing (NGS). However, these solutions are often not sensitive enough to determine minimal residual disease (MRD), can be confounded by the use of mAb therapeutics, or require bone marrow biopsies, subject to tissue biopsy limitations, such as sample bias, and invasiveness.